R M Fleischmann
Overview
Explore the profile of R M Fleischmann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
1937
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fleischmann R
Arthritis Rheum
. 2009 Oct;
60(11):3225-8.
PMID: 19877057
Progressive multifocal leukoencephalopathy (PML) is a rare brain disease caused by reactivation of the JC virus. Herein, a case of PML in association with rituximab treatment in a patient with...
2.
Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis
Davis Jr J, van der Heijde D, Braun J, Dougados M, Clegg D, Kivitz A, et al.
Ann Rheum Dis
. 2007 Oct;
67(3):346-52.
PMID: 17967833
Objective: Evaluate long-term safety and efficacy of etanercept treatment in patients with ankylosing spondylitis (AS). Methods: Patients with AS who previously participated in a randomised controlled trial (RCT) of etanercept...
3.
Fleischmann R, Tesser J, Schiff M, Schechtman J, Burmester G, Bennett R, et al.
Ann Rheum Dis
. 2006 Jan;
65(8):1006-12.
PMID: 16396977
Objective: To determine the safety profile of anakinra after extended exposure in a diverse clinical trial population of patients with rheumatoid arthritis. Methods: A six month, randomised, double blind phase...
4.
Fleischmann R, Cohen S, Moreland L, Schiff M, Mease P, Smith D, et al.
Curr Med Res Opin
. 2005 Aug;
21(8):1181-90.
PMID: 16083527
Objective: Infliximab plus methotrexate (MTX) is approved for the treatment of rheumatoid arthritis (RA). Based on the benefit/risk profile of this combination therapy, lower doses of MTX would be preferable...
5.
Fleischmann R
Rheumatology (Oxford)
. 2003 Jun;
42 Suppl 2:ii29-35.
PMID: 12817093
Anakinra (Kineret; Amgen Inc., Thousand Oaks, CA) is the first and only recombinant human interleukin-1 receptor antagonist available for therapeutic use. It has been approved by the US Food and...
6.
Bathon J, Martin R, Fleischmann R, Tesser J, Schiff M, Keystone E, et al.
N Engl J Med
. 2000 Nov;
343(22):1586-93.
PMID: 11096165
Background: Etanercept, which blocks the action of tumor necrosis factor, reduces disease activity in patients with long-standing rheumatoid arthritis. Its efficacy in reducing disease activity and preventing joint damage in...
7.
St Clair E, Cohen S, Lee M, Fleischmann R, Lee S, Moreland L, et al.
J Rheumatol
. 2000 Aug;
27(8):1855-63.
PMID: 10955324
Objective: To determine the safety and potential clinical efficacy of primary and booster injections of a DR4/1 peptide in patients with active rheumatoid arthritis (RA) despite methotrexate therapy. METHODS. Subjects...
8.
Roth S, Fleischmann R, Burch F, Dietz F, Bockow B, Rapoport R, et al.
Arch Intern Med
. 2000 Mar;
160(6):853-60.
PMID: 10737286
Background: Although opioid analgesics have well-defined efficacy and safety in treatment of chronic cancer pain, further research is needed to define their role in treatment of chronic noncancer pain. Objective:...
9.
Fleischmann R
Clin Ther
. 1999 Oct;
21(9):1429-42; discussion 1427-8.
PMID: 10509842
Early diagnosis and prompt treatment can improve outcomes in rheumatoid arthritis (RA). Significant joint damage occurs early in the course of the disease, when RA is most aggressive. Many rheumatologists...
10.
Moreland L, Schiff M, Baumgartner S, Tindall E, Fleischmann R, Bulpitt K, et al.
Ann Intern Med
. 1999 Mar;
130(6):478-86.
PMID: 10075615
Background: In a phase II study, etanercept (recombinant human tumor necrosis factor receptor [p75]:Fc fusion protein) safely produced rapid, dose-dependent improvement in rheumatoid arthritis over 3 months. Objective: To confirm...